Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7792914 | 0.83 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1NPSR1KMT2AMAPK1 | |
| SCHEMBL392071 | 0.82 | TDP1 (0.38) | ALDH1A1L3MBTL1KMT2AMAPK1CYP2C19 | |
| SCHEMBL7784129 | 0.81 | CYP1A2 (0.47) | ALDH1A1L3MBTL1NPSR1KMT2AGLA | |
| SCHEMBL391859 | 0.77 | KMT2A (0.67) | ALDH1A1L3MBTL1NPSR1KMT2AMAPK1 | |
| SCHEMBL12495320 | 0.77 | KMT2A (0.63) | ALDH1A1L3MBTL1NPSR1KMT2AMAPK1 | |
| SCHEMBL28748453 | 0.76 | KMT2A (0.50) | ALDH1A1L3MBTL1KMT2AMAPK1CYP1A2 | |
| SCHEMBL11945535 | 0.75 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1KMT2AMAPK1CYP1A2 | |
| SCHEMBL25077858 | 0.74 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1NOTUMKMT2AGLA | |
| SCHEMBL28748494 | 0.74 | KMT2A (0.48) | ALDH1A1L3MBTL1KMT2AMAPK1CYP1A2 | |
| SCHEMBL28748478 | 0.73 | KMT2A (0.50) | ALDH1A1L3MBTL1NPSR1KMT2AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364973-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8653088-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2361905-B1 | Heterocyclic Inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-01-17 | — | — | US | disclosed |
| US-8299076-B2 | crystalline form of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; for hyperproliferative diseases, such as cancer and inflammation in mammals; crystallization under acidic condition | ARRAY BIOPHARMA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8211920-B2 | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8101639-B2 | 6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101611-B2 | Substituted pyridazines inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1922307-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | disclosed |
| EP-1967516-B1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7601718-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | ARRAY BIOPHARMA, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1723/4885L3MBTL1 1913/4885NOTUM 2912/4885 |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | BRAF, NRAS, MAP3K1 | ALDH1A1 2121/4885L3MBTL1 2864/4885NOTUM 2521/4885 |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | ALDH1A1 1533/4885L3MBTL1 1875/4885NOTUM 2574/4885 |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | GSK3A, GSK3B, GSKIP | ALDH1A1 4703/4885L3MBTL1 3833/4885NOTUM 1281/4885 |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, RAF1 | ALDH1A1 1827/4885L3MBTL1 1001/4885NOTUM 2243/4885 |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, CDK9 | ALDH1A1 2030/4885L3MBTL1 893/4885NOTUM 3319/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1992/4885L3MBTL1 1801/4885NOTUM 2967/4885 |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | ALDH1A1 1327/4885L3MBTL1 1579/4885NOTUM 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.